Streetbeat News

Products Services

CDTX

MundiPharma and Cidara Therapeutics have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Rezafungin, a treatment for invasive candidiasis in adults. This is a significant step towards the approval of the drug in the European Union.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 2:22 pm

MRMD

MariMed, Inc (OTCQX:MRMD) has announced a limited-time program called 'Small Batch Exclusives' that allows customers to purchase rare cannabis strains at its Panacea Wellness dispensaries in Massachusetts. The program will run from Oct. 13 to Nov. 11. Customers who purchase six strains will receive a free 3.5-gram jar featuring a mystery strain. The initiative is a lead-in to Green Wednesday, one of the biggest days of the year for cannabis sales.

Portfolio Pulse from Jelena Martinovic

October 13, 2023 | 2:04 pm

SNY

Sanofi has presented positive Phase 2b data for its drug amlitelimab at the European Academy of Dermatology and Venereology (EADV) 2023 Congress. The drug showed potential best-in-class profile in atopic dermatitis with up to 61.5% improvement in Eczema Area and Severity Index (EASI) score from baseline at week 16. The Phase 3 program for amlitelimab is set to start in the first half of 2024. Amlitelimab was well-tolerated and no new safety concerns were identified.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 2:03 pm

BNBUSD

ETHUSD

MATICUSD

UNIUSD

Decentralized crypto exchange Uniswap has introduced a beta version of its mobile application for Android users. Previously, the platform was only available on PC and iOS devices. The new app supports networks like Polygon, Arbitrum, Optimism, Base, and BNB Chain, with plans for future compatibility extensions. The wallet channels Ethereum transactions via a private pool to counter potential front-running and sandwich attacks.

Portfolio Pulse from Murtuza Merchant

October 13, 2023 | 1:54 pm

BLK

DRPRF

GOOG

JPM

MSFT

NFLX

SAVA

TSM

UNH

WFC

The UK's Competition and Markets Authority has approved Microsoft's $69B acquisition of Activision Blizzard. Google is testing generative AI functionalities for its search tool. Cassava Sciences faces controversy over scientific misconduct allegations. Ford is struggling with UAW negotiations. EHang shares are trading higher after obtaining a certificate for its EH216-S UAV system. OpenAI is valued at $90B and is close to selling shares. TSMC is seeking permanent US approval for chip supplies. Netflix plans to launch 'Netflix House' experiences. The Kroger-Albertsons deal faces potential legal challenges. Boeing and Spirit AeroSystems are inspecting 737 Max aircraft defects. Wells Fargo, JPMorgan, Citigroup, BlackRock, and UnitedHealth reported Q3 earnings. Porsche records a 10% surge in deliveries for the first three quarters.

Portfolio Pulse from Vandana Singh

October 13, 2023 | 1:48 pm

AMGN

BMY

Amgen has presented preliminary results from its first study of an experimental pill that selectively blocks the PRMT5 enzyme in cancer cells, showing five partial responses from 31 evaluable patients. This follows the announcement that a rival PRMT5 inhibitor developed by Mirati Therapeutics factored into Bristol Myers Squibb's decision to acquire the company.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 1:47 pm

RPTX

Repare Therapeutics (NASDAQ:RPTX) has reported positive initial data from its Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib. The combination demonstrated anti-tumor activity across multiple tumor types and genotypes. The company will host a conference call and webcast to discuss these results.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 1:41 pm

TRNR

Interactive Strength, Inc. d/b/a FORME (NASDAQ:TRNR) has announced a strategic partnership with healthcare payment provider Truemed. The collaboration allows U.S. customers to use funds from their HSA and FSA programs to purchase FORME's personal training and smart home gyms, resulting in average after-tax savings between 30% and 40%. This partnership is expected to enhance FORME's B2C positioning and complement its B2B initiative of acquiring CLMBR.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 1:34 pm

AAPL

CMTL

SAVA

TFC

TSLA

Comtech Telecommunications shares are trading higher by around 17%. Tesla's market share dips despite US EV sales climbing. Crypto market faces uncertainty due to 'Friday the 13th'. Ripple's Brendan Berry is using crypto to revolutionize cross-border payments. SEC may greenlight a spot Bitcoin ETF. Apple faces a class action lawsuit over AirTags. Kroger-Albertsons deal may face legal challenge in California. Boeing and Spirit AeroSystems accelerate inspection of 737 Max aircraft defect. Truist Financial charts a recovery path after 43% stock decline since its February peak. Alzheimer's-focused Cassava Sciences faces controversy as key collaborator accused of scientific misconduct.

Portfolio Pulse from Akanksha Bakshi

October 13, 2023 | 1:32 pm

ASLN

ASLAN Pharmaceuticals presented new data from a Phase 2b study of Eblasakimab in Atopic Dermatitis at the 32nd European Academy of Dermatology and Venereology Congress. The data shows Eblasakimab's potential as the first biologic in moderate-to-severe atopic dermatitis with a competitive efficacy profile with once-monthly dosing. A post-hoc analysis of patients with severe disease showed a 74.5% reduction in EASI score with 600 mg Eblasakimab for 16 weeks.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 1:31 pm